TScan Therapeutics Q4 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate, Sales $665.00K Miss $1.35M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $290.1M To Fund Operations Into Q1 Of 2027
Benzinga Newsdesk 1 year ago
EarningsNews
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 42.86 percent decrease over losses of $(0.21) per share
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 42.86 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent. This is a 90.78 percent decrease over sales of $7.21 million the same period last year.